April 28, 2017 8:03am

 

… Q1/17 financial results

The question will be who spent what and where is the result?

 

… SELL the hype and BUY real facts

 

Its cash positions and advancing trials that will drive any share movement

 

Mixed open expected

 

Pre-open indications:  seven (7) – 4 SELLS, 1 BUYS – portfolio safety and upside are my theme even if it means being early and leaving some money on the table

 

Critical information ahead of “our” universe’s open! I provide intelligence and analysis for short and near-term investment.

Readership is a team sport, are you on it?

 


 

Expectation is the word for 2017 – meeting the unknowns with the soon to be exposed concerns will be the subject of investing decisions throughout this year.

 

 

Dow futures are UP +0.05% and NASDAQ futures are UP +0.02%

 

 

U.S. stock index futures pointed to a mixed open on Friday after U.S. President Trump said there was a "chance that we could end up having a major, major conflict with North Korea."

European markets moved slightly lower as investors concentrated on new earnings reports and geopolitical tensions.

Asian markets traded weaker as comments from President Trump on an existing free trade pact with Seoul to payment for a sophisticated anti-missile system caught investors by surprise.

 

Data docket: GDP and employment cost index data are set to come out at 8:30 a.m. ET. Chicago PMI is due at 9:45 a.m. ET, with consumer sentiment coming out at 10:00 a.m. ET.

 

 

The cell therapy sector closed NEGATIVE on Thursday, POSITIVE on Wednesday, Tuesday and Monday and NEGATIVE last Friday.

The cell therapy sector’s record after the last 5 days (of 43 covered companies):

·         Thursday closed NEGATIVE with 25 decliners, 18 advancers and 0 flats;

·         Wednesday closed POSITIVE with 7 decliners, 32 advancers and 4 flats;

·         Tuesday closed POSITIVE with 11 decliners, 28 advancers and 4 flats;

·         Monday closed POSITIVE with 10 decliners, 32 advancers and 1 flat;

·         Friday closed NEGATIVE with 35 decliners, 5 advancers and 3 flats;

 

 

Remembering Thursday’s closing bell newsletter, “I stated the sector was … Overbought and was proven right yet again.”

  • Reiterating, “Pressure will mount as the weekend beckons.”

What did I see on Thursday, the NASDAQ closed  up +0.04% … adding to what I said yesterday, emotional influence takes its toll, but investors need to be careful of this newest apex while volatility traded near 10.7!

 

What else did I see: Thursday’s ranges –decliners overcame gainers …

… Decliners ranged from -0.19% <KITE> to -5.36% <ADVM> in 25 equities;

… Gainers ranged from +0.29% <BTX> to +6.35% <BSTG> in 18 equities;

 

It might just be another day of giving up some of the past week’s appreciation!

 

 

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades? 

Watch list:

  • The iShares Nasdaq Biotechnology (IBB) closed Thursday up +0.04% and is indicating a negative -0.51% in Friday’s pre-market;
  • The SPDR S&P Biotech ETF (XBI) closed Thursday up +0.91% and is NOT indicating in Friday pre-market;
  • The Health Care Select Sector SPDR ETF (XLV) closed up +0.21% Thursday and is NOT indicating in Friday’s pre-open;
  • The iShares Russell 2000 (IWM) closed down -0.03% on Thursday and is indicating a positive +0.26% Friday’s pre-open

 

 

Companies in my headlights - There is NO market timing but there are indications to consider!

AxoGen (AXGN) closed up +$0.30 to $12.15. There is $0.70 or +5.7% in the till; April’s share pricing started at $10.28 and the value of the equity has risen and fallen balancing around $11.70 - SELL;

Biostage (BSTG) closed up +$0.02 to $0.336. The most recent 8-K, BSTG stated they’re about to execute a reverse of 1 for 2 and not greater than 1 for 20. Cash is getting VERY short; a reverse will lower shares outstanding and a needed or only available financing alternative – a warrant exercise will re-elevate the shares outstanding yet again.  BSTG desperately needs the cash. Remember, reverses have their institutional and historic downdrafts. Also to be noted, there is 1.85 million <versus the previous month’s 920.43 K > shares short out of the current float of 34.1 million shares, that’s 13.97%. Reliance on day trading as an investment incentive is NOT to be depended on - Maintaining SELL;

bluebird bio (BLUE) closed up +$0.40 to $89.05 after Wednesday’s $88.65 (+$0.90) following Tuesday’s $87.75 (+$2.10) after Monday’s $85.65 (+$3.25). Traders always get “antsy” when BLUE pops, do they stay or do they go – when I see $6.40 in an open till – Maintaining SELL;

Cellectis SA (CLLS) closed up +$0.34 to $24.17 following Wednesday’s $23.83 (+$0.26) after Tuesday’s $23.57 (+$0.26) following Monday’s $23.31 (+$0.66) following Friday’s $22.65 after last Thursday’s $23.00 ($0.87). I am NOT a “stayer” as traders usually drain the well. There is $2.21 or 9% in the till since 3/18 and the chart is “peaky”.  The aftermarket indication is a negative -$0.07 or -0.29% – Maintaining SELL;

MiMedx (MDXG) closed up +$0.30 to $11.40. MDXG’s revenue grew 36% over Q1/16 revenue as $72.6 million exceeded the upper end of MiMedx guidance range. MDXG’s recorded record revenue for the Q1/17 was $72.6 million, a $19.1 million or 36% increase over 2016 first quarter revenue of $53.5 million. Their strong Q1 performance and a gross profit margin of 88% indicate that MDXG is gaining and topping their comparables. The aftermarket indication is a positive +$0.65 or +5.70% - BUY;

Mesoblast (MESO) closed down -$0.03 to $12.31 following Wednesday’s $12.34 (+$0.55), Tuesday’s $11.78 (+$0.20), Monday’s $11.58 (+$0.38). A new high, as April ranged from $8.94 to $11.61. The chart has been trending and peaky but, traders love an open till with $1.11 or +9%. The month also started priced at $8.94. Overbought – Maintaining SELL;

Spark Therapeutics (ONCE) closed up +$0.60 to $57.84 following Wednesday’s $57.24 (+$0.32) following Tuesday’s $56.92 (+$2.08) after Monday’s $54.84 ($2.34). April ranged from $49.66 to $54.12. ONCE closed last Friday at $52.50 (-$1.62). There is approximately $7.60 (13.1%) since 4/11 in the till - Maintaining SELL;

 

 

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Henry’s comments are for informational purposes only and are not a substitute for personalized advice. Consult your advisor about what is best for you.